Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;36(2):345-346.
doi: 10.1007/s00198-024-07290-3. Epub 2024 Nov 1.

Bone density and microarchitecture in Graves' disease: evaluating treatment and vitamin D supplementation

Affiliations

Bone density and microarchitecture in Graves' disease: evaluating treatment and vitamin D supplementation

Wei-Zhen Tang et al. Osteoporos Int. 2025 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of interest: None.

Similar articles

References

    1. Grove-Laugesen D et al (2024) Changes in bone density and microarchitecture following treatment of Graves’ disease and the effects of vitamin D supplementation. A randomized clinical trial. Osteoporos Int. https://doi.org/10.1007/s00198-024-07241-y
    1. Bartalena L et al (2016) The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5:9–26 - DOI - PubMed - PMC
    1. O’brien CA et al (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835–1841 - DOI - PubMed
    1. Rymuza J et al (2022) Therapy with intravenous methylprednisolone pulses is associated with loss of bone microarchitecture in trabecular bone score -assessment among patients with moderate-to-severe Graves’ orbitopathy: a pilot study. Front Endocrinol (Lausanne) 13:893600 - DOI - PubMed
    1. Rymuza J et al (2019) Therapy of moderate-to-severe Graves’ orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density. Endocrine 64:308–315 - DOI - PubMed

LinkOut - more resources